Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

HEV vaccine advances to phase II trials

Sep. 28, 2001

Phase I trial begins for novel site-specific oral therapy for GI disorders

Sep. 28, 2001

BLA filed by Cangene for antihepatitis B product

Sep. 26, 2001

Superior efficacy demonstrated for SB-265610 compared to 5-ASA in experimental colitis model

Sep. 26, 2001

Erythromycin derivatives identified by Hokuriku active against H. pylori

Sep. 20, 2001

TAK-083 highly effective in the laboratory and in animals against H. pylori

Sep. 20, 2001

Muscarinic M3 antagonist YM-905 studied in experimental models of IBS symptoms

Sep. 18, 2001

Phase IIb clinical trial of ATL-1251 to begin in U.K. in IBS patients

Sep. 18, 2001

GT-160-246 as a promising approach to C. difficile colitis

Sep. 18, 2001

New HCV target discovered at Myriad Genetics, drug development program initiated

Sep. 10, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Korsana boosts Alzheimer’s work with reverse merger, $380M financing
BioWorld Science
Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...